Nektar Quiets Partnering Talk, Will Keep Oncology Drug For Itself
This article was originally published in The Pink Sheet Daily
Executive Summary
Auspicious data from a pair of Phase II studies has prompted the company to cease partnership discussions - and reassess its priorities.